- Home
- ABAT vs PBYI Comparison
ABAT vs PBYI Comparison
Compare ABAT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- PBYI
- Stock Information
- Founded
- ABAT 2011
- PBYI 2010
- Country
- ABAT United States
- PBYI United States
- Employees
- ABAT N/A
- PBYI N/A
- Industry
- ABAT Metal Mining
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- PBYI Health Care
- Exchange
- ABAT Nasdaq
- PBYI Nasdaq
- Market Cap
- ABAT 232.2M
- PBYI 237.2M
- IPO Year
- ABAT N/A
- PBYI N/A
- Fundamental
- Price
- ABAT $5.62
- PBYI $5.25
- Analyst Decision
- ABAT
- PBYI Strong Buy
- Analyst Count
- ABAT 0
- PBYI 1
- Target Price
- ABAT N/A
- PBYI $7.00
- AVG Volume (30 Days)
- ABAT 11.7M
- PBYI 512.6K
- Earning Date
- ABAT 11-14-2025
- PBYI 11-06-2025
- Dividend Yield
- ABAT N/A
- PBYI N/A
- EPS Growth
- ABAT N/A
- PBYI 434.29
- EPS
- ABAT N/A
- PBYI 0.97
- Revenue
- ABAT $4,290,224.00
- PBYI $238,062,000.00
- Revenue This Year
- ABAT $951.86
- PBYI N/A
- Revenue Next Year
- ABAT N/A
- PBYI N/A
- P/E Ratio
- ABAT N/A
- PBYI $5.33
- Revenue Growth
- ABAT 1148.97
- PBYI 8.63
- 52 Week Low
- ABAT $0.73
- PBYI $2.32
- 52 Week High
- ABAT $5.78
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- ABAT 74.23
- PBYI 65.12
- Support Level
- ABAT $4.82
- PBYI $4.37
- Resistance Level
- ABAT $5.78
- PBYI $4.79
- Average True Range (ATR)
- ABAT 0.60
- PBYI 0.22
- MACD
- ABAT 0.13
- PBYI 0.04
- Stochastic Oscillator
- ABAT 90.67
- PBYI 97.89
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.